Table 1.
Protective Drug | CAS #a | Ototoxinb | Optimal Concentrationc (μM) | Pretreatd (min) | Uptakee | MIC/MBCf | FDA targetg | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
Neo 1hr | Gent 1hr | Gent 6hr | Kan 24hr | Cis 24hr | |||||||
Estrogen-related | |||||||||||
| |||||||||||
raloxifene | 82640-04-8 | P | P | P | 10 | 0 | <.001 | normal | SERM | ||
| |||||||||||
tamoxifen | 10540-29-1 | P | P | 10 | 0 | n.s. | normal | SERM | |||
| |||||||||||
Serotonin and dopamine-related | |||||||||||
| |||||||||||
paroxetine | 110429-35-1 | P | P | P | P | 10 | 0 | n.s. | normal | SSRI | |
| |||||||||||
fluoxetine | 56296-78-7 | P | P | 50 | 0 | n.s. | normal | SSRI | |||
| |||||||||||
methiothepin | 74611-28-2 | P | P | P | 10 | 60 | n.s. | normal | Serotonin and dopamine agonist | ||
| |||||||||||
fluspirilene | 1841-19-6 | P | P | 10 | 0 | n.s. | normal | Dopamine antagonist | |||
| |||||||||||
Adenoreceptor-related | |||||||||||
| |||||||||||
phenoxybenzamine | 63-92-3 | P | P | P | 50 | 15 | <.05 | normal | antagonist at alpha adrenoceptor | ||
| |||||||||||
ractopamine | 90274-24-1 | P | P | P | P | 50 | 0 | <.01 | normal | agonist at beta adrenoceptor | |
| |||||||||||
Other classes | |||||||||||
| |||||||||||
loperamide | 34552-83-5 | P | P | P | P | 10 | 0 | n.s. | normal | μ-opioid receptor agonist | |
| |||||||||||
benzamil | 161804-20-2 | P | P | P | P | P | 50 | 0 | <.05 | MBC increased | Na/Ca channel blocker |
CAS # is the Chemical Abstract Service Registry number.
Shaded box with letter P indicates that a protective effect was observed with that protective compound-toxin combination. Neo=neomycin 1 hr exposure, Gent 1=gentamicin 1 hr exposure, Gent 6=gentamicin 6 hr exposure, Kan=kanamycin 24 hr exposure, Cis=cisplatin 24 hr exposure.
The lowest concentration of protective compound tested that confers the maximum protection against toxins.
The pretreatment time in minutes before toxin exposure that is needed to observe effective protection.
Whether gentamicin-Texas Red is able to enter cells in the presence of protective drug based on our fluorescence assay. The level of significance is indicated for drugs with altered uptake relative to GTTR only; n.s. = gentamicin entry not significantly different from GTTR only control. All drugs had uptake that was significantly different from embryo media only (EM) except for ractopamine and raloxifene.
Shows whether protective drug affected minimum inhibitory concentration (MIC) or minimum bactericidal concentration (MBC), where an increase in MIC or MBC indicates that neomycin is less effective at killing bacteria in presence of hair cell protective drug.
The accepted target of the drug in the literature, which may or may not describe the mode of action when protecting hair cells. SERM = selective estrogen receptor modulator; SSRI = selective serotonin reuptake inhibitor.